123 related articles for article (PubMed ID: 21330749)
1. Brain tumor and Gliadel wafer treatment.
Panigrahi M; Das PK; Parikh PM
Indian J Cancer; 2011; 48(1):11-7. PubMed ID: 21330749
[TBL] [Abstract][Full Text] [Related]
2. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
[TBL] [Abstract][Full Text] [Related]
3. The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
Nagpal S
Neurosurg Clin N Am; 2012 Apr; 23(2):289-95, ix. PubMed ID: 22440872
[TBL] [Abstract][Full Text] [Related]
4. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Lin SH; Kleinberg LR
Expert Rev Anticancer Ther; 2008 Mar; 8(3):343-59. PubMed ID: 18366283
[TBL] [Abstract][Full Text] [Related]
5. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
6. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
[TBL] [Abstract][Full Text] [Related]
7. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Westphal M; Ram Z; Riddle V; Hilt D; Bortey E;
Acta Neurochir (Wien); 2006 Mar; 148(3):269-75; discussion 275. PubMed ID: 16482400
[TBL] [Abstract][Full Text] [Related]
8. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control.
Ewend MG; Brem S; Gilbert M; Goodkin R; Penar PL; Varia M; Cush S; Carey LA
Clin Cancer Res; 2007 Jun; 13(12):3637-41. PubMed ID: 17575228
[TBL] [Abstract][Full Text] [Related]
9. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
Giese A; Kucinski T; Knopp U; Goldbrunner R; Hamel W; Mehdorn HM; Tonn JC; Hilt D; Westphal M
J Neurooncol; 2004 Feb; 66(3):351-60. PubMed ID: 15015668
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of the carmustine implant.
Fleming AB; Saltzman WM
Clin Pharmacokinet; 2002; 41(6):403-19. PubMed ID: 12074689
[TBL] [Abstract][Full Text] [Related]
11. In vitro Study of Serial Changes to Carmustine Wafers (Gliadel) with MR Imaging and Computed Tomography.
Doishita S; Shimono T; Yoneda T; Yamada E; Tsukamoto T; Takemori D; Kimura D; Tatekawa H; Sakamoto S; Miki Y
Magn Reson Med Sci; 2018 Jan; 17(1):58-66. PubMed ID: 28867760
[TBL] [Abstract][Full Text] [Related]
12. [Results for Treatment of Newly-Diagnosed Glioblastoma Using Carmustine Wafers(Gliadel
Kumabe T; Shibahara I; Saito R
No Shinkei Geka; 2018 May; 46(5):367-376. PubMed ID: 29794312
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review.
Zhang YD; Dai RY; Chen Z; Zhang YH; He XZ; Zhou J
Turk Neurosurg; 2014; 24(5):639-45. PubMed ID: 25269031
[TBL] [Abstract][Full Text] [Related]
14. MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation.
Sippl C; Ketter R; Bohr L; Kim YJ; List M; Oertel J; Urbschat S
Neurosurgery; 2019 Jul; 85(1):147-155. PubMed ID: 29846701
[TBL] [Abstract][Full Text] [Related]
15. miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
Sippl C; Ketter R; Braun L; Teping F; Schoeneberger L; Kim YJ; List M; Nakhoda A; Wemmert S; Oertel J; Urbschat S
Acta Neurochir (Wien); 2019 Nov; 161(11):2299-2309. PubMed ID: 31478117
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic effect on glioblastoma of chemotherapy on the basis of brain irradiation].
Qin D; Mo H; Ou G
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):168-9. PubMed ID: 11783028
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.
Belanich M; Pastor M; Randall T; Guerra D; Kibitel J; Alas L; Li B; Citron M; Wasserman P; White A; Eyre H; Jaeckle K; Schulman S; Rector D; Prados M; Coons S; Shapiro W; Yarosh D
Cancer Res; 1996 Feb; 56(4):783-8. PubMed ID: 8631014
[TBL] [Abstract][Full Text] [Related]
20. [Combined treatment of glyal and metastatic tumors of the brain].
Fadeev BP; Zhabina RM
Vestn Khir Im I I Grek; 2005; 164(1):80-2. PubMed ID: 15957817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
